https://mindmedicinelaw.com/briefing/ketamine-and-esketamine-safety-during-breastfeeding-systematic-review-insights-20261009-48565The Psychedelic Journalen2026-10-10T15:08:05.018596+00:00Ketamine and Esketamine Safety During Breastfeeding: Systematic Review Insightsketamine, esketamine, breastfeeding safety, pharmacokinetics, infant outcomes, systematic review, perinatal psychiatry, lactation guidelines, public health, clinical researchhttps://mindmedicinelaw.com/briefing/techbio-3-0-ai-driven-closed-loop-drug-discovery-in-psychedelics-20261009-48581The Psychedelic Journalen2026-10-10T15:07:47.840550+00:00TechBio 3.0: AI-Driven Closed-Loop Drug Discovery in Psychedelicstechbio 3.0, ai drug discovery, generative chemistry, automated experimentation, psychedelic research, cns drug development, regulatory policy, closed-loop systems, fda, drug discovery automationhttps://mindmedicinelaw.com/briefing/blinding-ethics-and-safety-in-psychedelic-clinical-trials-20261009-48643The Psychedelic Journalen2026-10-10T15:07:19.195925+00:00Blinding, Ethics, and Safety in Psychedelic Clinical Trialspsychedelic clinical trials, blinding integrity, ethics in research, participant safety, institutional review board, FDA guidance, trial methodology, adverse event reporting, expectancy bias, regulatory standardshttps://mindmedicinelaw.com/briefing/ayahuasca-integration-in-yaqui-led-mental-health-care-sonora-mexico-20261009-48527The Psychedelic Journalen2026-10-10T15:06:01.022538+00:00Ayahuasca Integration in Yaqui-Led Mental Health Care, Sonora, Mexicoayahuasca, indigenous mental health, yaqui clinic, intercultural medicine, psychedelic care, mexico drug law, community-based care, indigenous sovereignty, psychedelic research, cultural adaptationhttps://mindmedicinelaw.com/briefing/fda-signals-openness-to-ibogaine-clinical-trials-in-the-us-20261009-48558The Psychedelic Journalen2026-10-10T15:05:43.767357+00:00FDA Signals Openness to Ibogaine Clinical Trials in the USfda, ibogaine, clinical trials, psychedelic research, addiction treatment, regulatory policy, schedule i substances, cardiac safety, drug developmenthttps://mindmedicinelaw.com/briefing/ai-driven-suicide-risk-prediction-in-bipolar-depression-implications-for-psyched-20261008-48568The Psychedelic Journalen2026-10-10T15:08:42.704054+00:00AI-Driven Suicide Risk Prediction in Bipolar Depression: Implications for Psychedelic Trialssuicide risk prediction, bipolar depression, machine learning, psychedelic clinical trials, risk stratification, FDA protocols, electronic health records, AI in psychiatry, trial inclusion criteriahttps://mindmedicinelaw.com/briefing/chiral-psychoactive-drugs-environmental-and-forensic-implications-20261008-48547The Psychedelic Journalen2026-10-10T15:08:24.472962+00:00Chiral Psychoactive Drugs: Environmental and Forensic Implicationschiral drugs, psychoactive substances, wastewater analysis, forensic chemistry, environmental monitoring, enantiomers, bioaccumulation, public health, stereoselectivity, regulatory policyhttps://mindmedicinelaw.com/briefing/interoceptive-training-in-psilocybin-therapy-for-cancer-patients-20261008-48529The Psychedelic Journalen2026-10-10T15:06:56.801088+00:00Interoceptive Training in Psilocybin Therapy for Cancer Patientspsilocybin therapy, cancer patients, interoceptive training, somatic practices, clinical trial design, depression and anxiety, phenomenological taxonomy, psychedelic-assisted therapy, therapeutic preparation, regulatory implicationshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-music-playlists-lack-phase-based-structure-20261008-48528The Psychedelic Journalen2026-10-10T15:06:39.263431+00:00Psilocybin Therapy Music Playlists Lack Phase-Based Structurepsilocybin therapy, music playlists, clinical trial protocols, pharmacodynamic phases, standardization, FDA regulation, psychedelic-assisted therapy, playlist curation, reproducibility, patient safetyhttps://mindmedicinelaw.com/briefing/lsd-alters-working-memory-brain-activity-in-mdd-rct-insights-20261008-48530The Psychedelic Journalen2026-10-10T15:06:21.806658+00:00LSD Alters Working Memory Brain Activity in MDD: RCT Insightslsd, major depressive disorder, working memory, fMRI, psychedelic clinical trials, cognitive effects, mood disorders, neuroimaging, trial design, regulatory policyhttps://mindmedicinelaw.com/briefing/rct-on-circular-breathwork-safety-in-trauma-affected-adults-20261008-48221The Psychedelic Journalen2026-10-09T15:08:03.205067+00:00RCT on Circular Breathwork Safety in Trauma-Affected Adultscircular breathwork, randomized controlled trial, adverse events, subclinical depression, childhood trauma, non-pharmacological interventions, psychotherapy safety, conscious connected breathwork, clinical integrationhttps://mindmedicinelaw.com/briefing/how-psychedelics-restructure-brain-information-flow-new-evidence-20261008-48189The Psychedelic Journalen2026-10-09T15:06:24.214542+00:00How Psychedelics Restructure Brain Information Flow: New Evidencepsychedelics, brain information flow, self-coupling, multivariate information decomposition, LSD, psilocybin, ketamine, DMT, clinical trial design, neural mechanismshttps://mindmedicinelaw.com/briefing/cooling-methods-for-drug-induced-hyperthermia-systematic-review-insights-for-eme-20261007-48210The Psychedelic Journalen2026-10-09T22:04:19.540472+00:00Cooling Methods for Drug-Induced Hyperthermia: Systematic Review Insights for Emergency Caredrug-induced hyperthermia, cooling methods, emergency medicine, psychedelic risk management, novel psychoactive substances, ice water immersion, pre-hospital protocols, systematic review, acute care, clinical guidelineshttps://mindmedicinelaw.com/briefing/italy-s-multi-indicator-surveillance-of-ats-and-synthetic-cathinones-20261007-48191The Psychedelic Journalen2026-10-09T15:09:34.167373+00:00Italy’s Multi-Indicator Surveillance of ATS and Synthetic Cathinonesitaly drug surveillance, amphetamine-type stimulants, synthetic cathinones, wastewater-based epidemiology, drug seizures, toxicological data, novel psychoactive substances, public health policy, regional drug trends, multi-indicator monitoringhttps://mindmedicinelaw.com/briefing/tianeptine-and-opioid-peptides-modulate-hippocampal-ampars-in-mice-20261007-48222The Psychedelic Journalen2026-10-09T15:09:11.795259+00:00Tianeptine and Opioid Peptides Modulate Hippocampal AMPARs in Micetianeptine, opioid peptides, ampar function, hippocampus, rapid-acting antidepressants, glutamatergic transmission, opioid receptor, abuse potential, psychiatric drug developmenthttps://mindmedicinelaw.com/briefing/durability-of-implanted-vagus-nerve-stimulation-in-us-trd-care-20261007-48230The Psychedelic Journalen2026-10-09T15:08:41.155552+00:00Durability of Implanted Vagus Nerve Stimulation in US TRD Carevagus nerve stimulation, treatment-resistant depression, RECOVER trial, neuromodulation, durability of response, mechanisms of action, psychedelic adjuncts, FDA approval, clinical guidelines, biomarkershttps://mindmedicinelaw.com/briefing/clearmind-s-fda-policy-submission-psychedelic-therapy-pathways-in-the-u-s-20261007-48308The Psychedelic Journalen2026-10-09T15:08:19.102012+00:00Clearmind's FDA Policy Submission: Psychedelic Therapy Pathways in the U.S.clearmind, fda, psychedelic therapy, drug development, policy recommendations, regulatory framework, clinical trials, industry engagement, us federal policyhttps://mindmedicinelaw.com/briefing/lsd-induced-brain-rhythm-changes-meg-study-advances-biomarker-research-20261007-48193The Psychedelic Journalen2026-10-09T15:07:44.185062+00:00LSD-Induced Brain Rhythm Changes: MEG Study Advances Biomarker Researchlsd, meg study, brain rhythms, neural complexity, psychedelic biomarkers, clinical trial design, spectral analysis, fractal dimension, neuroscience researchhttps://mindmedicinelaw.com/briefing/ketamine-for-ptsd-in-military-populations-systematic-review-insights-20261007-48232The Psychedelic Journalen2026-10-09T15:07:21.018452+00:00Ketamine for PTSD in Military Populations: Systematic Review Insightsketamine, ptsd, military veterans, systematic review, clinical trials, safety reporting, psychedelic research, treatment-resistant, policy implicationshttps://mindmedicinelaw.com/briefing/psychoactive-alkaloid-distribution-in-australian-acacia-policy-and-conservation--20261007-48243The Psychedelic Journalen2026-10-09T15:07:03.819594+00:00Psychoactive Alkaloid Distribution in Australian Acacia: Policy and Conservation Implicationsacacia alkaloids, dmt in plants, psychedelic plant policy, australian conservation, phytochemical profiling, multi-tissue analysis, endangered species, psychoactive compounds, drug law enforcement, sustainable harvestinghttps://mindmedicinelaw.com/briefing/va-launches-psilocybin-depression-study-for-u-s-veterans-20261007-48309The Psychedelic Journalen2026-10-09T15:06:44.398742+00:00VA Launches Psilocybin Depression Study for U.S. Veteransveterans affairs, psilocybin clinical trial, depression treatment, federal psychedelic research, mental health policy, veterans mental health, psychedelic-assisted therapy, clinical trial design, regulatory implications